Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
2051-1426
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program ; volume:7 ; number:1 ; day:3 ; month:4 ; year:2019 ; pages:1-9 ; date:12.2019
Journal for ImmunoTherapy of Cancer ; 7, Heft 1 (3.4.2019), 1-9, 12.2019

Urheber
Verzoni, Elena
Cartenì, Giacomo
Cortesi, Enrico
Giannarelli, Diana
Giglio, Andrea De
Sabbatini, Roberto
Buti, Sebastiano
Rossetti, Sabrina
Cognetti, Francesco
Rastelli, Francesca
Sobrero, Alberto
Turci, Daniele
Sternberg, Cora N.
Porta, Camillo
Cappuzzo, Federico
Tortora, Giampaolo
Tassinari, Davide
Panni, Stefano
Pazzola, Antonio
Surico, Gianmarco
Raimondi, Alessandra
Giorgi, Ugo De
Procopio, Giuseppe
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/s40425-019-0579-z
URN
urn:nbn:de:101:1-2019042400474404348485
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:51 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Verzoni, Elena
  • Cartenì, Giacomo
  • Cortesi, Enrico
  • Giannarelli, Diana
  • Giglio, Andrea De
  • Sabbatini, Roberto
  • Buti, Sebastiano
  • Rossetti, Sabrina
  • Cognetti, Francesco
  • Rastelli, Francesca
  • Sobrero, Alberto
  • Turci, Daniele
  • Sternberg, Cora N.
  • Porta, Camillo
  • Cappuzzo, Federico
  • Tortora, Giampaolo
  • Tassinari, Davide
  • Panni, Stefano
  • Pazzola, Antonio
  • Surico, Gianmarco
  • Raimondi, Alessandra
  • Giorgi, Ugo De
  • Procopio, Giuseppe
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma

Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma

Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab

Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab

Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab

Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab

Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab

Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab

Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma

Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma

Ramsay-Hunt syndrome and subsequent sensory neuropathy as potential immune-related adverse events of nivolumab: a case report

Ramsay-Hunt syndrome and subsequent sensory neuropathy as potential immune-related adverse events of nivolumab: a case report

Renal Immune-Related Adverse Event Difficult to Diagnose during Nivolumab Treatment for Hypopharyngeal Carcinoma: Case Report

Renal Immune-Related Adverse Event Difficult to Diagnose during Nivolumab Treatment for Hypopharyngeal Carcinoma: Case Report

Brain connectivity extended and expanded

Brain connectivity extended and expanded

Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study

Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study

Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England

Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England

Calcitriol-mediated hypercalcemia as an immune-related adverse event in a patient receiving nivolumab and ipilimumab for metastatic renal cell carcinoma, case report

Calcitriol-mediated hypercalcemia as an immune-related adverse event in a patient receiving nivolumab and ipilimumab for metastatic renal cell carcinoma, case report

Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report

Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report

Verbundene Objekte